The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials
Abstract
BACKGROUND: A variety of antiarrhythmic drugs have been used to prevent recurrence of atrial fibrillation after conversion to sinus rhythm. We performed a systematic review to determine the effect of long-term treatment with those drugs on death, embolisms, adverse effects, and atrial fibrillation recurrence. METHODS: We searched MEDLINE, EMBASE, the Cochrane Library (all up to May 2005), and the reference lists of retrieved articles. We included randomized controlled trials that compared any antiarrhythmic against control (placebo or no treatment) or another antiarrhythmic, for more than 6 months. Postoperative atrial fibrillation was excluded. Two evaluators independently reviewed the retrieved studies and extracted all data. Disagreements were resolved by discussion. All results were calculated at 1 year of follow-up. RESULTS: Forty-four trials were included, with a total of 11 322 patients. Several class IA (disopyramide phosphate, quinidine sulfate), class IC (flecainide acetate, propafenone hydrochloride), and class III (amiodarone, dofetilide, sotalol hydrochloride) drugs significantly reduced recurrence of atrial fibrillation (number needed to treat, 2-9), but all increased withdrawals due to adverse effects (number needed to harm [NNH], 9-27) and all but amiodarone and propafenone increased proarrhythmia (NNH, 17-119). Class IA drugs, pooled, were associated with increased mortality compared with controls (Peto odds ratio, 2.39; 95% confidence interval, 1.03-5.59; P = .04; NNH, 109). No other antiarrhythmic showed a significant effect on mortality compared with controls. We could not analyze other outcomes because data were lacking. CONCLUSION: Class IA, IC, and III drugs are effective in maintaining sinus rhythm but increase adverse effects, and class IA drugs may increase mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
Wazni, O. M., Marrouche, N. F., Martin, D. O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., et al. (2005) · JAMA · doi:10.1001/jama.293.21.2634 · Cited by 1,121
Amiodarone versus sotalol for atrial fibrillation
Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041705 · Cited by 749
Wattigney, W. A., Mensah, G. A., & Croft, J. B. (2003) · Circulation · doi:10.1161/01.cir.0000083722.42033.0a · Cited by 505
Outpatient treatment of recent-onset atrial fibrillation with the “Pill-in-the-Pocket” approach
Alboni, P., Botto, G. L., Baldi, N., Luzi, M., Russo, V., Gianfranchi, L., Marchi, P., Calzolari, M., Solano, A., Baroffio, R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041233 · Cited by 479
Singh, S., Zoble, R. G., Yellen, L., Brodsky, M. A., Feld, G. K., Berk, M., & Billing, C. B. (2000) · Circulation · doi:10.1161/01.cir.102.19.2385 · Cited by 433
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial
FETSCH, T. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.04.015 · Cited by 334
Rate vs Rhythm Control in Patients With Atrial Fibrillation: A Meta-analysis
de Denus, S. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.258 · Cited by 239
Suppression of paroxysmal atrial tachyarrhythmias—results of the SOPAT trial
PATTEN, M., MAAS, R., BAUER, P., LUDERITZ, B., SONNTAG, F., DLUZNIEWSKI, M., HATALA, R., OPOLSKI, G., MULLER, H., & MEINERTZ, T. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.014 · Cited by 157
Cited by
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Potentially inappropriate medications in the elderly: a French consensus panel list
Laroche, M.-L., Charmes, J.-P., & Merle, L. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0324-2 · Cited by 517
Valsartan for prevention of recurrent atrial fibrillation
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805710 · Cited by 441
Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A. J., Cappato, R., Cosio, F., Crijns, H., Diener, H.-C., Goette, A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp235 · Cited by 202
Kirchhof, P., Andresen, D., Bosch, R., Borggrefe, M., Meinertz, T., Parade, U., Ravens, U., Samol, A., Steinbeck, G., Treszl, A., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60570-4 · Cited by 176
Metadata
- Authors
- Lafuente-Lafuente, C., Mouly, S., Longás-Tejero, M. A., Mahé, I., & Bergmann, J.-F.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2006-04-10
- Volume
- 166
- Issue
- 7
- Pages
- 719
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2107934559
- Cited by
- 288
- References
- 10
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1001/archinte.166.7.719
- The paper
- Lafuente-Lafuente, C., Mouly, S., Longás-Tejero, M. A., Mahé, I., & Bergmann, J.-F. (2006). Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials. Archives of Internal Medicine. https://doi.org/10.1001/archinte.166.7.719
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
